natgillin/translations-raw huggingface dataset:
After a subcutaneous administration of 1 mg/kg the systemic bioavailability is 69% in cats and 88% in dogs. 
Po subkutanem injiciranju robenakoksiba v odmerku 1 mg/kg je bila sistemska biorazpoložljivost pri mačkah 69 % in pri psih 88 %.
Robenacoxib tablets are therefore COX-1 sparing at recommended doses in dogs. 
Robenakoksib tablete torej nimajo vpliva na COX-1 v priporočenih odmerkih pri psih.
The cyclooxygenase 1 enzyme (COX-1) which has protective functions, e.g. in the digestive tract and kidneys, is not inhibited by robenacoxib. 
Encima ciklooksigenaza 1 (COX-1), ki ima zaščitno funkcijo, npr. v prebavnem traktu in ledvicah, robenakoksib ne zavira.
Onsior 5 mg Onsior 10 mg Onsior 20 mg Onsior 40 mg 
Onsior 5 mg Onsior 10 mg Onsior 20 mg Onsior 40 mg robenakoksib
For cats, Onsior solution for injection or tablets may be used interchangeably in accordance with the indications and directions of use approved for each pharmaceutical form. 
Pri mačkah se lahko zamenljivo uporabi zdravilo Onsior raztopina za injiciranje ali zdravilo Onsior tablete, skladno z indikacijami in navodili za uporabo, odobrenimi za vsako farmacevtsko obliko.
Acute musculo-skeletal disorders: treat for up to 6 days. 
2 tableti Akutna mišičnoskeletna obolenja: zdravite do 6 dni.
Pharmacotherapeutic group: Anti-inflammatory and anti-rheumatic products, non-steroids, coxibs. 
Farmakoterapevtska skupina: Nesteroidna protivnetna in protirevmatična zdravila, koksibi.
INDICATION(S) Not applicable. 
INDIKACIJA(E) Ni smiselno.
20 to < 40 
20 do < 40
7 tablets 14 tablets 28 tablets 70 tablets 30 x 1 tablets 60 x 1 tablets 
7 tablet 14 tablet 28 tablet 70 tablet 30 x 1 tableta 60 x 1 tableta
Orthopaedic surgery: Give as a single oral treatment prior to orthopaedic surgery. 
Ortopedski operativni posegi: Pred ortopedskim operativnim posegom dajte zdravilo v obliki enkratnega peroralnega odmerka.
Pre-treatment with other anti-inflammatory medicines may result in additional or increased adverse effects and, accordingly, a treatment-free period with such substances should be observed for at least 24 hours before the commencement of treatment with Onsior. 
Predhodno zdravljenje z drugimi zdravili s protivnetnim učinkom lahko povzroči dodatne ali povečane neželene učinke, zato je treba pred pričetkom zdravljenja z zdravilom Onsior zagotoviti vsaj 24-urno obdobje brez zdravljenja s takšnimi snovmi.
Tablets are round, beige to brown and non-divisible. 
Tablete so okrogle, bež do rjave barve in nedeljive.
Number of tablets by size 
Število tablet glede na velikost
Differences between robenacoxib and placebo were significant (P<0.05) for the client specific outcome measures, but did not reach significance (P=0.07) for the feline musculoskeletal pain index. 
Razlike med robenakoksibom in placebom so bile signifikantne (P<0,05) za meritve izidov mačk, vendar niso bile signifikantne (P=0,07) za lestvico za merjenje mišičnoskeletne bolečine pri mačkah.
It selectively inhibits the cyclooxygenase 2 enzyme (COX-2), which is responsible for pain, inflammation or fever. 
Selektivno zavira encim ciklooksigenazo 2 (COX-2), ki je odgovoren za bolečino, vnetje ali povišano telesno temperaturo.
2 tablets 
2 tableti
Reversible inflammation at the injection site was noted in all groups (including controls) and was more severe in the 6 and 20 mg/kg dose groups. 
Na mestu vboda je bilo pri vseh skupinah, vključno s kontrolnimi, opaziti vnetje (močneje pri skupinah z odmerkoma 6 mg/kg in
Robenacoxib is a non-steroidal anti-inflammatory drug (NSAID). 
Robenakoksib je nesteroidno protivnetno zdravilo (NSAID).
After subcutaneous administration, the terminal half-life from blood was 1.1 h in cats and 1.2 h in dogs. 
Po subkutanem injiciranju je končni razpolovni čas 1,1 h pri mačkah in 1,2 h pri psih.
Repeated subcutaneous administration at dosages of 2-20 mg/kg produced no change in the blood profile, with neither bioaccumulation of robenacoxib nor enzyme induction. 
Ponavljajoče se subkutano injiciranje odmerkov 2-20 mg/kg ni povzročilo sprememb v krvni sliki, bioakumulacije robenakoksiba ali indukcije encimov.
Do not use concomitantly with corticosteroids or other non-steroidal anti-inflammatory drugs (NSAIDs). 
Ne uporabite sočasno s kortikosteroidi ali drugimi nesteroidnimi protivnetnimi zdravili (NSAID).
10 mg tablet: BE 20 mg tablet: CD 40 mg tablet: BCK 
5 mg tableta: AK 10 mg tableta: BE 20 mg tableta: CD 40 mg tableta: BCK
In small children, accidental ingestion increases the risk for NSAID adverse effects. 
Nenamerno zaužitje pri majhnih otrocih poveča tveganje za pojav neželenih učinkov NSAID.
Onsior must not be administered in conjunction with other NSAIDs or glucocorticosteroids. 
Zdravilo Onsior se ne sme uporabljati skupaj z drugimi zdravili iz skupine NSAID ali glukokortikoidi.
Vomiting and soft faeces were very common, decreased appetite and diarrhoea were common, and blood in the faeces was uncommon. 
Zelo pogosto sta bila prisotna bruhanje in mehko blato, pogosto zmanjšan apetit in diareja, medtem ko je bila kri v blatu prisotna občasno.
At the recommended dosage (2 mg/kg), analgesic, anti-inflammatory and anti-pyretic effects were demonstrated in an inflammation model, and in clinical trials, robenacoxib reduced pain and inflammation in cats undergoing orthopaedic or soft tissue surgery. 
V priporočenem odmerku (2 mg/kg) so bili pri vnetnem modelu vidni protibolečinski, protivnetni in antipiretični učinki, v kliničnih preizkusih pa je robenakoksib zmanjšal bolečino in vnetje pri mačkah, podvrženih ortopedskim operativnim posegom ali operativnim posegom na mehkih tkivih.
No safety data in the target population and no efficacy data in general exist for the combined treatment of robenacoxib and benazepril. 
Za zdravljenje s kombinacijo učinkovin robenakoksiba in benazeprila pri ciljni populaciji ni podatkov o varnosti in učinkovitosti na splošno.
Do not use after the expiry date stated on the label or blister after EXP. 
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, navedenega na ovojnini ali pretisnem omotu za oznako »EXP«.
10 to < 20 
10 do < 20
PARTICULARS TO APPEAR ON THE OUTER PACKAGE NATURE/TYPE: Cardboard box 
PODATKI NA ZUNANJI OVOJNINI VRSTA/TIP: Kartonska škatla
In the high dose group kidney weights were decreased and sporadically associated with renal tubular degeneration/ regeneration but not correlated with evidence of renal dysfunction on clinical pathology parameters. 
V skupini z visokim odmerkom so opazili zmanjšanje mase ledvic in občasno povezavo z ledvično tubularno degeneracijo/regeneracijo, kar pa ni bilo povezano s prisotnostjo ledvične disfunkcije, ki bi se odražala na kliničnih patoloških parametrih.
A dose-dependent increase in the QT interval, a decreased heart rate and corresponding increased respiratory rate were observed in laboratory studies. 
Pri laboratorijskih študijah so opazili od odmerka odvisno podaljšanje QT intervala, zmanjšan srčni utrip in odgovarjajočo povečano stopnjo dihanja.
In overdose studies conducted in cats, there was a dose-dependent increase in the QT interval. 
Pri študijah prevelikega odmerjanja, narejenih na mačkah, so opazili od odmerka odvisno podaljšanje
Slight pain at injection site was commonly reported. 
Rahla bolečina na mestu injiciranja je bila opisana pogosto.
Name and address of the manufacturers responsible for batch release 
Ime in naslov proizvajalcev zdravila, odgovornih za sproščanje serij
Robenacoxib is a non-steroidal anti-inflammatory drug (NSAID) of the coxib class. 
Robenakoksib je nesteroidno protivnetno zdravilo (NSAID) iz skupine koksibov.
Concurrent administration of potentially nephrotoxic medicines should be avoided as there might be an increased risk of renal toxicity. 
Izogibajte se sočasni uporabi potencialno nefrotoksičnih snovi, ker obstaja povečano tveganje toksičnega vpliva na ledvice.
In dogs treated up to 2 weeks no increases in liver enzyme activities were observed. 
Pri psih, zdravljenih do 2 tednov, ni bilo opaziti porasta aktivnosti jetrnih encimov, vendar pa je bila ta pogosto povišana pri dolgotrajnem zdravljenju.
If use cannot be avoided, these cats require careful monitoring. 
Če se uporabi v takih primerih ne morete izogniti, potrebujejo te mačke strog veterinarski nadzor.
In clinical trials robenacoxib tablets reduced the lameness and inflammation of dogs with chronic osteoarthritis. 
V kliničnih preizkusih so tablete robenakoksiba zmanjšale šepanje in vnetje pri psih s kroničnim osteoartritisom.
The pharmacokinetics of robenacoxib injection do not differ between male and female cats and dogs, and are linear over the range of 0.25-4 mg/kg in dogs. 
Farmakokinetika injiciranega robenakoksiba se med mačkami in psi ženskega in moškega spola ne razlikuje ter je pri psih pri odmerkih 0,25-4 mg/kg linearna.
In an inflammation model in cats, robenacoxib injection had analgesic, anti-inflammatory and anti-pyretic effects and a rapid onset of action (0.5 h). 
Pri vnetnem modelu pri mačkah je robenakoksib v obliki injekcije učinkoval protibolečinsko, protivnetno in antipiretično, s hitrim nastopom učinka (0,5 h).
Multi-dose amber glass vial containing 20 ml solution for injection, closed with a rubber stopper and sealed with an aluminium cap. One vial packed in a cardboard box. 
Večodmerna viala iz temnega stekla vsebuje 20 ml raztopine za injiciranje in je zaprta z gumijastim zamaškom in aluminijasto zaporko.
and a slightly lower AUC (1,069 ng·h/ml). 
AUC (1383 ng·h/ml).
Tablets are round, beige to brown, non-divisible and with imprints “NA” on one side and “AK” on the other side. 
Tablete so okrogle, bež do rjave barve, nedeljive in z vtisnjenima oznakama »NA« na eni in »AK« na drugi strani.
For long-term treatment, once a clinical response has been observed, the dose of Onsior can be adjusted to the lowest effective individual dose reflecting that the degree of pain and inflammation associated with chronic osteoarthritis may vary over time. 
Pri dolgotrajnem zdravljenju lahko po vidnem kliničnem odzivu odmerek zdravila Onsior prilagodite na najnižji učinkovit individualen odmerek, pri tem pa upoštevajte, da se stopnja bolečine in vnetja,
Administer subcutaneously to cats or dogs approximately 30 minutes before the start of surgery, for example around the time of induction of general anaesthesia, at a dose of 1 ml per 10 kg of body weight (2 mg/kg). 
Dajte subkutano mačkam ali psom približno 30 minut pred začetkom operativnega posega, npr. v času uvajanja splošne anestezije, v odmerku 1 ml na 10 kg telesne mase (2 mg/kg).
Moderate or severe pain at injection site was uncommon. 
Zmerna ali huda bolečina na mestu injiciranja je bila opisana občasno.
COX-2 is the inducible form of the enzyme which is responsible for the production of mediators including PGE2 which induce pain, inflammation or fever. 
COX-2 je inducibilna oblika encima, ki je odgovorna za sintezo mediatorjev, vključno s PGE2, ki inducirajo bolečino, vnetje ali povišano telesno temperaturo.
Each tablet contains 6 mg robenacoxib. 
Vsaka tableta vsebuje 6 mg robenakoksiba.
A. MANUFACTURERS RESPONSIBLE FOR BATCH RELEASE 
A. PROIZVAJALCI ZDRAVILA, ODGOVORNI ZA SPROŠČANJE SERIJ
5 to < 10 
5 do < 10
Administer the solution subcutaneously to cats or dogs approximately 30 minutes before the start of surgery, for example around the time of induction of general anaesthesia, at a dose of 1 ml per 10 kg of body weight (2 mg/kg). 
Raztopino dajte subkutano mačkam in psom približno 30 minut pred pričetkom operativnega posega, npr. v času uvajanja splošne anestezije, v odmerku 1 ml na 10 kg telesne mase (2 mg/kg).
Sodium metabisulphite (E 223) 
robenakoksib 20 mg Pomožna snov: natrijev metabisulfit (E 223)
In case of accidental ingestion or self-injection, seek medical advice immediately and show the package leaflet or the label to the physician. 
V primeru nenamernega zaužitja ali samo-injiciranja se takoj posvetujte z zdravnikom in mu pokažite navodila za uporabo ali ovojnino.
Robenacoxib is excreted predominantly via the biliary route in cats (∼70%) and dogs (∼65%) and the remainder via the kidneys. 
Pretežno se izloča z žolčem tako pri mačkah (∼ 70 %) kot pri psih (∼ 65 %), preostali del pa preko ledvic.
The recommended dose of robenacoxib is 1 mg/kg body weight with a range 1-2.4 mg/kg. 
Priporočen odmerek robenakoksiba je 1 mg/kg telesne mase v območju 1-2,4 mg/kg.
INDICATION(S) For the treatment of pain and inflammation of chronic osteoarthritis in dogs. 
INDIKACIJA(E) Za zdravljenje bolečine in vnetja v povezavi s kroničnim osteoartritisom pri psih.
2.5 to < 5 
2,5 do < 5
(IC50 0.04 μM) as compared to COX-1 (IC50 7.9 μM). 
kot za COX-1 (IC50 7,9 μM).
Pain at injection site was commonly reported. 
Bolečina na mestu injiciranja je bila opisana pogosto.
In most cases the liver enzyme activities either stabilised or decreased with continued treatment. 
Z nadaljevanjem zdravljenja se je v večini primerov aktivnost jetrnih encimov stabilizirala ali zmanjšala.
2.5 to < 6 
2,5 do < 6
The recommended dose of robenacoxib is 1 mg/kg body weight with a range 1-2 mg/kg. 
Priporočen odmerek robenakoksiba je 1 mg/kg telesne mase v območju 1-2 mg/kg.
COX-1 is the constitutive form of the enzyme and has protective functions, e.g. in the gastrointestinal tract and kidneys. 
COX-1 je konstitutivna oblika encima, ki ima zaščitno funkcijo, npr. v prebavnem traktu in ledvicah.
If use cannot be avoided, these dogs require careful monitoring. 
Če se uporabi v takih primerih ne morete izogniti, potrebujejo ti psi strog veterinarski nadzor.
Peak blood concentrations of robenacoxib are attained rapidly after subcutaneous injection in cats and dogs. 
Po subkutanem injiciranju robenakoksiba so bile pri mačkah in psih maksimalne koncentracije v krvi hitro dosežene.
STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S) Each tablet contains the following amount of robenacoxib and bears the imprint “NA” on one side and the following imprint on the other side: 
NAVEDBA UČINKOVIN(E) IN DRUGIH SESTAVIN Vsaka tableta vsebuje naslednje količine robenakoksiba, z vtisnjeno oznako »NA« na eni strani in naslednjimi vtisnjenimi oznakami na drugi strani: robenakoksib/tableta Vtisnjene oznake 5 mg
Treatment should not exceed one dose (either tablet or injection) per day. 
Zdravljenje ne sme preseči enega odmerka (tablet ali raztopine za injiciranje) na dan. Upoštevajte dejstvo, da je priporočen odmerek za vsako od farmacevtskih oblik različen.
Co-administration of robenacoxib non-flavoured tablets with food produced no delay in Tmax, but slightly lower values for Cmax (832 ng/ml) and AUC (782 ng·h/ml). 
Pri vnosu robenakoksib tablet brez okusa, skupaj s hrano, ni prišlo do podaljšanja pri Tmax, ampak do rahlo nižje koncentracije Cmax (832 ng/ml) in AUC (782 ng·h/ml).
Robenacoxib persists longer and in higher concentrations at sites of inflammation than in blood. 
Na vnetnih mestih ostaja robenakoksib dlje časa in v višjih koncentracijah kot v krvi.
In vivo, robenacoxib solution for injection produced marked inhibition of COX-2 activity and had no effect on COX-1 activity. 
In vivo je robenakoksib raztopina za injiciranje povzročila vidno inhibicijo COX-2 aktivnosti, medtem ko na COX-1 aktivnost ni vplivala.
Increases in liver enzyme activities associated with clinical signs of anorexia, apathy or vomiting were uncommon. 
Občasno je bila povečana aktivnost jetrnih encimov v povezavi s kliničnimi znaki anoreksije, apatije ali bruhanja.
For the treatment of pain and inflammation associated with acute or chronic musculoskeletal disorders in cats. 
Za zdravljenje bolečine in vnetja v povezavi z akutnimi ali kroničnimi mišičnoskeletnimi obolenji pri mačkah.
The pharmacokinetics of robenacoxib do not differ between male and female dogs, and are linear over the range 0.5-8 mg/kg. 
Farmakokinetika robenakoksiba se med psicami in psi ne razlikuje ter je pri odmerkih od 0,5 do 8 mg/kg telesne mase linearna.
In an in vitro whole blood assay in dogs, robenacoxib was approximately 140 fold selective for COX-2 
In vitro raziskave celokupne krvi pri psih so pokazale, da je selektivnost robenakoksiba približno 140
In the in vitro whole blood assay in cats, the selectivity of robenacoxib was approximately 500 fold higher for COX-2 (IC50 0.058 μM) as compared to COX-1 (IC50 28.9 μM). 
In vitro raziskave celokupne krvi pri mačkah so pokazale, da je selektivnost robenakoksiba približno 500-krat večja za COX-2 (IC50 0,058 μM) kot za COX-1 (IC50 28,9 μM).
After intravenous administration robenacoxib was rapidly cleared from blood (CL of 0.44 L/kg/h in cats and 0.81 L/kg/h in dogs) with an elimination t1/2 of 1.1 h in cats and 0.8 h in dogs. 
Robenakoksib se po intravenskem dajanju iz krvi izloča hitro (CL 0,44 l/kg/h pri mačkah in 0,81 l/kg/h pri psih), z razpolovnim časom t1/2 1,1 h pri mačkah in 0,8 h pri psih.
In artificially induced inflammation in cats and dogs, robenacoxib reduced pain, inflammation and fever at the recommended doses with a rapid onset of action (1 h). 
Pri umetno induciranih vnetjih pri mačkah in psih je robenakoksib v priporočenih odmerkih hitro (1 h) zmanjšal bolečino, vnetje in povišano telesno temperaturo.
STATEMENT OF ACTIVE SUBSTANCES 20 mg/ml Robenacoxib 
20 mg/ml robenakoksiba
After oral administration of tablets, the terminal half-life from blood was 1.7 h. Robenacoxib persists longer and at higher concentrations at sites of inflammation than in blood. 
Po peroralnem vnosu tablet je končni razpolovni čas 1,7 h. Na vnetnih mestih ostaja robenakoksib dlje časa in v višjih koncentracijah kot v krvi.
This product reduced in clinical trials pain and inflammation in cats and dogs undergoing orthopaedic or soft tissue surgery. 
To zdravilo je v kliničnih preizkusih zmanjšalo bolečino in vnetje pri mačkah in psih, podvrženih ortopedskim operativnim posegom ali operativnim posegom na mehkih tkivih.
Robenacoxib is rapidly cleared from blood (CL 0.44 L/kg/h) with an elimination t1/2 of 1.1 h after intravenous administration. 
Robenakoksib se iz krvi izloča hitro (CL 0,44 l/kg/h), z razpolovnim časom t1/2 1,1 h po intravenskem dajanju.
After surgery, once daily treatment may be continued for up to two further days. 
Po operativnem posegu lahko še dva dni nadaljujete zdravljenje z enim odmerkom zdravila na dan.
NAME OF THE VETERINARY MEDICINAL PRODUCT Onsior 6 mg 
IME ZDRAVILA ZA UPORABO V VETERINARSKI MEDICINI Onsior 6 mg robenakoksib
This product reduced in clinical trials the lameness and inflammation of dogs with chronic osteoarthritis. 
To zdravilo je v kliničnih preizkusih zmanjšalo šepanje in vnetje pri psih s kroničnim osteoartritisom.
The interchangeable use of Onsior tablets and Onsior solution for injection has been tested in a target animal safety study and was shown to be well tolerated by cats. 
V varnostni študiji na ciljnih živalskih vrstah je bila preizkušena zamenljiva uporaba zdravila Onsior tablete in zdravila Onsior raztopina za injiciranje, ki je pokazala dobro prenašanje pri mačkah.
Onsior solution for injection for cats and dogs is available in a cardboard box containing 1 vial with 20 ml solution for injection. 
Zdravilo Onsior raztopina za injiciranje za mačke in pse je na voljo v kartonski škatli, ki vsebuje 1
Robenacoxib is excreted predominantly via the biliary route (∼65%) and the remainder via the kidneys. 
Pretežno se izloča z žolčem (∼ 65 %), preostali del pa preko ledvic.
Do not use in dogs suffering from stomach ulcer or with liver disease. 
Ne uporabite pri psih z razjedami na prebavilih ali z jetrnimi obolenji.
Citric acid monohydrate Sodium metabisulphite (E 223) Sodium hydroxide Water for injections 
6.1 Seznam pomožnih snovi makrogol 400 etanol, brezvodni poloksamer 188 citronska kislina monohidrat natrijev metabisulfit (E 223) natrijev hidroksid voda za injekcije
Gastrointestinal adverse events (vomiting, soft faeces or diarrhoea) were commonly reported, but most cases were mild and recovered without treatment. 
Neželeni učinki na prebavilih (bruhanje, mehko blato ali diareja) so bili opisani pogosto, vendar so bili v večini primerov blagi in so izzveneli brez zdravljenja.
At a dose of 1-2 mg/kg body weight, robenacoxib tablets produced a marked inhibition of COX-2 activity in cats and had no effect on COX-1 activity. 
Pri mačkah so tablete robenakoksiba v odmerkih 1-2 mg/kg telesne mase povzročile vidno inhibicijo COX-2 aktivnosti, medtem ko na COX-1 aktivnost niso vplivale.
Onsior 5 mg tablets for dogs Onsior 10 mg tablets for dogs Onsior 20 mg tablets for dogs Onsior 40 mg tablets for dogs Robenacoxib 
Onsior 5 mg tablete za pse Onsior 10 mg tablete za pse Onsior 20 mg tablete za pse Onsior 40 mg tablete za pse robenakoksib
Robenacoxib has a relatively small volume of distribution (Vss of 190 ml/kg in cats and 240 ml/kg in dogs) and is highly bound to plasma proteins (>99%). 
Robenakoksib ima razmeroma majhno prostornino porazdelitve (Vss 190 ml/kg pri mačkah in Vss 240 ml/kg pri psih) in se močno veže na plazemske proteine (> 99 %).
Robenacoxib has a relatively small volume of distribution (Vss 190 ml/kg) and is highly bound to plasma proteins (>99%). 
Robenakoksib ima razmeroma majhno prostornino porazdelitve (Vss 190 ml/kg) in se močno veže na plazemske proteine (> 99 %).
Robenacoxib has a relatively small volume of distribution (Vss 240 ml/kg) and is highly bound to plasma proteins (>99%). 
Robenakoksib ima razmeroma majhno prostornino porazdelitve (Vss 240 ml/kg) in se močno veže na plazemske proteine (> 99 %).
In healthy young cats aged 10 months, once daily subcutaneous administration of robenacoxib at doses of 4 mg/kg (twice RTD) for 2 consecutive days and 10 mg/kg (5 times RTD) for 3 consecutive days did not produce any signs of toxicity, including signs of gastrointestinal, kidney or liver toxicity and had no effect on bleeding time. 
Pri zdravih mačkah, starih 10 mesecev, se po 2 zaporednih dnevih subkutanega prejemanja robenakoksiba v odmerku 4 mg/kg (2-kratni PTO) enkrat dnevno in po 3 zaporednih dnevih subkutanega prejemanja robenakoksiba v odmerku 10 mg/kg (5-kratni PTO) enkrat dnevno znaki toksičnosti na prebavilih, ledvicah ali jetrih niso pojavili, prav tako ni bilo vpliva na čas krvavitve.
Elanco France S.A.S 26 Rue de la Chapelle 68330 Huningue FRANCE 
26 Rue de la Chapelle 68330 Huningue Francija
Yeast powder Cellulose, microcrystalline Flavour, artificial beef Cellulose, powdered Povidone (K-30) Crospovidone Silica, colloidal anhydrous Magnesium stearate 
6.1 Seznam pomožnih snovi kvas v prahu celuloza, mikrokristalna umetna goveja aroma celuloza, uprašena povidon (K-30) krospovidon silicijev dioksid, koloidni, brezvodni magnezijev stearat
In clinical trials in cats, robenacoxib tablets reduced pain and inflammation associated with acute musculo-skeletal disorders and reduced the need for rescue treatment when given as premedication in case of orthopaedic surgery, in combination with opioids. 
V kliničnih preizkusih pri mačkah so tablete robenakoksiba zmanjšale bolečino in vnetje v povezavi z akutnimi mišičnoskeletnimi obolenji ter potrebo po uporabi drugih hitro delujočih zdravil za lajšanje bolečin, kadar so ga dajali kot premedikacijo v kombinaciji z opioidi v primeru ortopedskih operativnih posegov.
Do not use in case of hypersensitivity to robenacoxib or to any of the ingredients of the tablets. 
Ne uporabite v primerih preobčutljivosti na robenakoksib ali na katerokoli sestavino tablet.
Yeast powder Cellulose, microcrystalline Povidone (K-30) Crospovidone Silica, colloidal anhydrous Magnesium stearate 
6.1 Seznam pomožnih snovi kvas v prahu celuloza, mikrokristalna povidon (K-30) krospovidon silicijev dioksid, koloidni, brezvodni magnezijev stearat
After a dosage of 2 mg/kg a Tmax of 1 h (cats and dogs), a Cmax of 1,464 ng/ml (cats) and 615 ng/ml (dogs), and an AUC of 3,128 ng·h/ml (cats) and 2,180 ng·h/ml (dogs) is obtained. 
Pri odmerku 2 mg/kg je bila maksimalna koncentracija v plazmi (Cmax 1464 ng/ml pri mačkah in 615 ng/ml pri psih) dosežena v 1 uri (Tmax), površina pod krivuljo koncentracije v krvi v odvisnosti od časa (AUC) pa je znašala pri mačkah 3128 ng·h/ml in pri psih 2180 ng·h/ml.